Biologics contracting worth $2.6bn this year, says HiTec
Demand for biopharmaceutical contract manufacturing will grow 16 per cent a year over the next five years, according to analysis by US market research group HighTech Business Decisions.
Archives for June 10, 2009
FTC calls for biogenerics path and end of “pay for delay” deals
The US Federal Trade Commission (FTC) believes that an effective FOB approval pathway and laws preventing “pay-for-delay” deals are the only ways of reducing the cost of biologic drugs.
Satyam records post-fraud profits
Satyam, the Indian IT outsourcing company whose former chairman admitted to a $1bn (€700m) fraud in January, has posted a $10.9m unaudited profit for February, sending shares soaring.
Predictive toxicology allies aim to cut late stage failures
Gentronix has partnered with Apredica to provide a predictive toxicology service, which the companies believe can reduce the failure rates of drugs in late-stage development, saving clients time and money.
SA API importer accused of fraud
A South African importer of APIs that claimed to have deals with Pfizer, Teva and Merck & Co is accused of fraud, with investigators likening the case to Bernard Madoff’s Ponzi scheme.
Alfa hopes to make industrial chemistry an ART
Sweden’s Alfa Laval says ART PR49, its combined chemical reactor and heat transfer plate, improves the efficiency of chemical production and helps reduce energy costs.